Anton Y Peleg1, Jocelyn M Choo2, Katherine M Langan3, Deirdre Edgeworth4, Dominic Keating5, John Wilson5, Geraint B Rogers2, Tom Kotsimbos6. 1. Department of Infectious Disease, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia; Biomedicine Discovery Institute, Department of Microbiology, Monash University, Melbourne, Australia. 2. Department Infection & Immunity Theme, South Australian Health and Medical Research Institute, Adelaide, Australia. 3. Department of Infectious Disease, The Alfred Hospital and Central Clinical School, Monash University, Melbourne, Australia. 4. Department Respiratory Medicine, The Alfred, Melbourne, Australia. 5. Department Respiratory Medicine, The Alfred, Melbourne, Australia; Department of Medicine, Monash University, Melbourne, Australia. 6. Department Respiratory Medicine, The Alfred, Melbourne, Australia; Department of Medicine, Monash University, Melbourne, Australia. Electronic address: tom.kotsimbos@monash.edu.
Abstract
BACKGROUND: G551D is a class III mutation of the cystic fibrosis transmembrane regulator (CFTR) that results in impaired chloride channel function in cystic fibrosis (CF). Ivacaftor, a CFTR-potentiating agent improves sweat chloride, weight, lung function, and pulmonary exacerbation rate in CF patients with G551D mutations, but its effect on the airway microbiome remains poorly characterised. METHODS:Twenty CF patients with at least one G551D mutation from a single centre were recruited to a 4month double-blind, placebo-controlled, crossover study of ivacaftor with 28days of active treatment. Sputum microbiota composition was assessed by 16S rRNA gene amplicon sequencing and quantitative PCR at five key time points, along with regular clinical review, respiratory function assessment, and peripheral blood testing. RESULTS: No significant difference in microbiota composition was observed in subjects following ivacaftor treatment or placebo (PERMANOVA P=0.95, square root ECV=-4.94, 9479 permutations). Microbiota composition variance was significantly greater between subjects, than within subjects over time (P<0.0001, Mann Whitney U test), and an additional within-patient paired assessment of microbiota similarity was therefore performed. Again, change in microbiota composition was not significantly greater during treatment with ivacaftor compared to placebo (Wilcoxon test, P=0.51). A significant change in microbiota composition was however associated with any change in antibiotic exposure, regardless of whether ivacaftor or placebo was administered (P=0.006). In a small, subgroup analysis of subjects whose antibiotic exposure did not change within the study period, a significant reduction in total bacterial load was observed during treatment with ivacaftor (P=0.004, two-tailed paired Student's t-test). CONCLUSIONS: The short-term impact of ivacaftor therapy on sputum microbiota composition in patients with G551D mutations are modest compared to those resulting from antibiotic exposure, and may be masked by changes in antibiotic treatment regimen.
RCT Entities:
BACKGROUND:G551D is a class III mutation of the cystic fibrosis transmembrane regulator (CFTR) that results in impaired chloride channel function in cystic fibrosis (CF). Ivacaftor, a CFTR-potentiating agent improves sweat chloride, weight, lung function, and pulmonary exacerbation rate in CFpatients with G551D mutations, but its effect on the airway microbiome remains poorly characterised. METHODS: Twenty CFpatients with at least one G551D mutation from a single centre were recruited to a 4month double-blind, placebo-controlled, crossover study of ivacaftor with 28days of active treatment. Sputum microbiota composition was assessed by 16S rRNA gene amplicon sequencing and quantitative PCR at five key time points, along with regular clinical review, respiratory function assessment, and peripheral blood testing. RESULTS: No significant difference in microbiota composition was observed in subjects following ivacaftor treatment or placebo (PERMANOVA P=0.95, square root ECV=-4.94, 9479 permutations). Microbiota composition variance was significantly greater between subjects, than within subjects over time (P<0.0001, Mann Whitney U test), and an additional within-patient paired assessment of microbiota similarity was therefore performed. Again, change in microbiota composition was not significantly greater during treatment with ivacaftor compared to placebo (Wilcoxon test, P=0.51). A significant change in microbiota composition was however associated with any change in antibiotic exposure, regardless of whether ivacaftor or placebo was administered (P=0.006). In a small, subgroup analysis of subjects whose antibiotic exposure did not change within the study period, a significant reduction in total bacterial load was observed during treatment with ivacaftor (P=0.004, two-tailed paired Student's t-test). CONCLUSIONS: The short-term impact of ivacaftor therapy on sputum microbiota composition in patients with G551D mutations are modest compared to those resulting from antibiotic exposure, and may be masked by changes in antibiotic treatment regimen.
Authors: J Kirk Harris; Brandie D Wagner; Edith T Zemanick; Charles E Robertson; Mark J Stevens; Sonya L Heltshe; Steven M Rowe; Scott D Sagel Journal: Ann Am Thorac Soc Date: 2020-02
Authors: Lo M Sosinski; Christian Martin H; Kerri A Neugebauer; Lydia-Ann J Ghuneim; Douglas V Guzior; Alicia Castillo-Bahena; Jenna Mielke; Ryan Thomas; Marc McClelland; Doug Conrad; Robert A Quinn Journal: J Cyst Fibros Date: 2021-11-22 Impact factor: 5.527
Authors: Maartje I Kristensen; Karin M de Winter-de Groot; Gitte Berkers; Mei Ling J N Chu; Kayleigh Arp; Sophie Ghijsen; Harry G M Heijerman; Hubertus G M Arets; Christof J Majoor; Hettie M Janssens; Renske van der Meer; Debby Bogaert; Cornelis K van der Ent Journal: J Pers Med Date: 2021-04-27
Authors: Lindsay J Caverly; Junnan Lu; Lisa A Carmody; Linda M Kalikin; Kerby Shedden; Kristopher Opron; Michelle Azar; Shannon Cahalan; Bridget Foster; Donald R VanDevanter; Richard H Simon; John J LiPuma Journal: Ann Am Thorac Soc Date: 2019-12
Authors: Martina Oriano; Leonardo Terranova; Antonio Teri; Samantha Sottotetti; Luca Ruggiero; Camilla Tafuro; Paola Marchisio; Andrea Gramegna; Francesco Amati; Fabrizio Nava; Elisa Franceschi; Lisa Cariani; Francesco Blasi; Stefano Aliberti Journal: Multidiscip Respir Med Date: 2019-01-31
Authors: Robyn L Marsh; Maria T Nelson; Chris E Pope; Amanda J Leach; Lucas R Hoffman; Anne B Chang; Heidi C Smith-Vaughan Journal: Pneumonia (Nathan) Date: 2018-07-05